Survey - Lack of Confidence in Clinical Trial Data Delaying Drug Development
Clinical data challenges are hindering pharmaceutical companies' abilities to bring more drugs to the market faster. These challenges were addressed with a study commissioned by Oracle Health Sciences and conducted by Pharma Intelligence.
To begin, the survey revealed that 57 percent of the clinical researchers believe that their clinical data issues result in trial delays. In addition to trial delays, 81 percent of respondents cited data governance issues as the biggest challenge in meeting regulatory compliance which include duplicate data/inconsistent data, data quality, and data integrity/traceability.
When asked what the top three operational challenges were with their clinical trial data, 51 percent cited data completeness, 45 percent said data quality and 43 percent, data cleaning. Not surprisingly, over three-fourths of respondents cited inconsistent data and missing patient data as the most critical clinical data problems to catch in clinical trials.
To conclude, the top three risks highlighted by the research include the need for additional data reconciliation; incomplete data to determine efficacy and patient replacements.
Read the full release here.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Phase III SELECT-GCA Trial Results Lead to FDA Approval of Rinvoq for Giant Cell Arteritis
April 30th 2025Rinvoq (upadacitinib) becomes the first oral JAK inhibitor approved by the FDA for the treatment of giant cell arteritis in adults, following robust data from the Phase III SELECT-GCA trial demonstrating its efficacy in achieving sustained remission and reducing glucocorticoid exposure.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
